Payer Agreements: Splitting the Risk

Date: October 23, 2011
Pages: 41
Price:
US$ 695.00
License [?]:
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PFF9D033B67EN
Leaflet:

Download PDF Leaflet

Payer Agreements: Splitting the Risk
Budgets are tight. Payer funding for new products is dwindling. And for pharmaceutical companies, market access is more and more difficult to attain.

Across the UK, the US, Canada, Australia and parts of Europe, payer schemes are increasingly de rigueur. Schemes advanced by pharmaceutical companies either aim to grapple financial issues such as price volume agreements, or they tackle uncertainty by addressing increased data collection.

Report Overview

In Payer Agreements: Splitting the Risk, FirstWord Dossier offers a complete and concise overview of payer schemes by definition and category. Based on an array of expert interviews, the report discusses the key drivers behind the evolution of payer schemes from financial imperatives to market uncertainty. Most importantly, the report defines—country by country—emerging trends based on current case studies and tackles the big question: What are the key features that will ensure success?

Key features
  • Detailed examination of the role of agreements in global pricing, reimbursement and market access
  • Discussion of the drivers for schemes, including HTA and financial challenges
  • Country-by-country trends illustrated with case studies
  • Expert insight into the role of schemes and their evolution
  • Analysis of the pros and cons of agreements

Key Benefits
  • Definitions and categories of schemes
  • Expert insight from key regulatory bodies
  • Comprehensive references to key literature

Key Questions Asked
  • What principles should be used in designing schemes?
  • When should companies offer risk-sharing agreements?
  • How can European risk-sharing be implemented in the US?
  • What is the current state of play with schemes globally?
  • What changes are likely in the future?

Who Should Read This Report
  • Market access directors and managers
  • Health economics professionals
  • Pharmacoeconomics professionals
  • Health Outcomes / Outcomes Research professionals
  • Pricing and Reimbursement teams
  • Government and regulatory affairs analysts
  • Marketing research/business intelligence managers
  • Government and regulatory affairs analysts
EXECUTIVE SUMMARY

CURRENT AGREEMENTS WITH PAYERS ACROSS AUSTRALIA, EUROPE, CANADA AND THE US

Introduction
Defining and categorizing schemes
  Definitions from the literature
  UK definition and categorization
Drivers for schemes
  Financial challenges
  HTA and saying ‘no’
  Dealing with uncertainty

COUNTRY TRENDS IN SCHEMES AND SELECTED CASE STUDIES

Australia
  Bosentan patient registry
Canada
  Clozaril money-back guarantee
Denmark
  No cure, no pay for Diovan
France
  Risperdal refund
Germany
  Aclasta refund scheme
Italy
  Tarceva discount scheme
  Sutent discount scheme
Serbia
  Avastin, Erbitux and MabCampath rebate schemes
Sweden
  Crestor and ezetimibe coverage with evidence development
UK
  Multiple Sclerosis Risk Sharing Scheme
  Velcade money back guarantee
  Lucentis dose capping scheme
US
  Proscar refund scheme
  Zocor refund scheme
  Januvia guarantee scheme
  Sanofi and Proctor & Gamble pay for fractures scheme

POTENTIALS AND PITFALLS OF AGREEMENTS

Fit with pricing and reimbursement environments
Pros and cons
Reality check

CONCLUSIONS

Too early to say
Maybe necessary, but not sufficient
Exploring uncertainty, not discounting in the future

ACKNOWLEDGEMENTS
Skip to top


Ask Your Question

Payer Agreements: Splitting the Risk
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: